GLP 1 Receptor Agonists and GIP-GLP 1 Receptor Agonists for People with and without Diabetes in 2024
Jeremy Gilbert, MD, FRCPC
Topics: Diabetes, GLP 1 RA
- Details
Objectives
Learning Objectives:
- Review evidence for using GLP 1 RAs and GIP-GLP1 RAs for people with and without diabetes
- Describe how to practically use these agents and minimize side effects
- Discuss potential benefits of these agents beyond A1c lowering and weight loss
Faculty
Jeremy Gilbert MD, FRCPC
Program Director, Adult Endocrinology and Metabolism
Sunnybrook Health Sciences Centre
Dr. Gilbert is heavily involved in the management, advancement and continuing medical education of Diabetes. Jeremy completed his medical degree, internal medicine training and endocrinology residency at the University of Toronto. He is an associate professor at the University of Toronto. He is the program director for adult endocrinology and metabolism at the University of Toronto. He has authored a chapter in the 2013 and 2018 Diabetes Canada Guidelines and was a member of the steering committee of the 2018 Diabetes Canada Guidelines. He is on the executive and is a national editor for the Canadian Journal of Diabetes. He is a passionate teacher and his academic interest is in undergraduate, postgraduate and continuing medical education in diabetes and endocrinology. He has received numerous awards for outstanding teaching.